Clinical Trial Update: This Phase II/III, Multicenter Study is Designed to Evaluate the Safety and Clinical Activity of AL3810 in Patients [Phase 2, Phase 3]

View source ↗

Summary

A multicenter Phase II/III trial is designed to evaluate the safety and clinical activity of AL3810 in extensive-stage small cell lung cancer, with unknown curr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Extensive-stage Small Cell Lung Cancer

Drugs mentioned

• AL3810

Snippet

Sponsor: Haihe Biopharma Co., Ltd. | Conditions: Extensive-stage Small Cell Lung Cancer | Phase 2, Phase 3 | Status: UNKNOWN